Patients

TIF Signs Agreement With Resonance Health To Deploy FerriSmart®
News

TIF Signs Agreement With Resonance Health To Deploy FerriSmart®

FerriSmart is an AI-driven system for automated real-time measurement of liver-iron concentrate (LIC) in patients, using non-invasive MRI-based technology. Under the Letter of Agreement, TIF will engage with National Thalassaemia…
La Repubblica: Gene Editing Cured Two Siblings With Thalassaemia In Italy
Clinical News

La Repubblica: Gene Editing Cured Two Siblings With Thalassaemia In Italy

Cured of thalassemia, thanks to gene editing. According to a recent news report published in the Italian newspaper La Repubblica, Erika and Emanuele Guarini, two siblings from Pistoia, Tuscany, aged…
Virtual Event: 1st Global Forum On Access To Safe Blood Products For Patients In Need Of Regular Transfusion – 5 November 2021
Blood

Virtual Event: 1st Global Forum On Access To Safe Blood Products For Patients In Need Of Regular Transfusion – 5 November 2021

Expected Outcomes An understanding of the strategic vision and goals for blood safety and the protection of the blood supply, especially in low-income settings; A better understanding of the key…
COMING UP: 1st Global Forum On Access To Safe Blood Products For Patients In Need Of Regular Transfusion – 5 November 2021
News

COMING UP: 1st Global Forum On Access To Safe Blood Products For Patients In Need Of Regular Transfusion – 5 November 2021

Expected Outcomes An understanding of the strategic vision and goals for blood safety and the protection of the blood supply, especially in low-income settings; A better understanding of the key…
Thalassemia Foundation of Canada to Host its National Thalassemia Conference on October 23-24
Member News

Thalassemia Foundation of Canada to Host its National Thalassemia Conference on October 23-24

The Thalassemia Foundation of Canada, a long-time member of TIF, will be holding its 2-day Virtual National Conference on Thalassaemia this weekend, October 23-24, at 12:00-16:00 EDT. The Conference aims at…
EdiGene Announces First Patient Enrolment In Phase I Clinical Trial Of Gene-editing Therapy ET-01 For Patients With β-Thalassaemia
News

EdiGene Announces First Patient Enrolment In Phase I Clinical Trial Of Gene-editing Therapy ET-01 For Patients With β-Thalassaemia

The Chinese biotechnology company EdiGene announced yesterday that the first patient was enrolled in the multicentre, Phase I clinical study of its investigational gene editing hematopoietic stem cell therapy ET-01…
TIF Position Statement: Demanding Access To Existing And Upcoming Gene Therapies For β-Thalassaemia
Clinical News

TIF Position Statement: Demanding Access To Existing And Upcoming Gene Therapies For β-Thalassaemia

The Thalassaemia International Federation (TIF) is expressing its grave disappointment over the recent announcement of Bluebird Bio regarding the “wind-down” of its operations in Europe and the exclusive disposal of…
TIF Issues Charter of Priorities (CoP) For The Global PKD Patient Community
News

TIF Issues Charter of Priorities (CoP) For The Global PKD Patient Community

In the context of its educational and advocacy efforts within the field of other rare anaemias, beyond thalassaemia and sickle cell disease (SCD), and aiming, in particular, at the support…
Schaltfläche "Zurück zum Anfang"